Table 1.
Items Assessing Primary Care Physicians’ PrEP Motivation and Behavioral Skills.
| Motivation: PrEP attitudes (1=completely disagree, 5=completely agree) | M (SD) |
Factor loading |
| 1. PrEP can be a cost-effective HIV prevention intervention if used with an appropriate population of patients. |
3.98 (0.86) |
0.57 |
| 2. PrEP is too costly to warrant its use. (R) | 3.31 (0.94) |
0.66 |
| 3. Individuals who are at risk for HIV should be encouraged to use condoms rather than to take PrEP. (R) |
2.92 (1.13) |
0.60 |
| 4. Individuals who take PrEP are likely to increase their sexual risk behaviors and negate the benefits of PrEP. (R) |
3.25 (1.04) |
0.77 |
| 5. Money should not be spent on HIV prevention for men who have sex with men. (R) |
4.45 (0.88) |
0.57 |
| 6. There is insufficient evidence at this time for me to consider PrEP an appropriate preventive treatment option. (R) |
3.66 (1.09) |
0.72 |
| 7. Widespread use of PrEP will likely significantly increase rates of antiretroviral resistance. (R) |
3.02 (0.93) |
0.63 |
| 8. Individuals who are prescribed PrEP are not likely to adhere to their medication. (R) |
3.27 (0.91) |
0.68 |
|
Behavioral skills: Comfort prescribing PrEP (1=completely uncomfortable, 5=completely comfortable) |
||
| Please rate how uncomfortable or comfortable you are with the following: | ||
| 1. Determining whether a patient’s sexual risk behaviors warrant the use of PrEP. |
3.64 (1.11) |
0.82 |
| 2. Determining whether a patient’s IV drug use behaviors warrant the use of PrEP. |
3.75 (1.17) |
0.80 |
| 3. Discussing the efficacy of PrEP with a patient. | 3.58 (1.24) |
0.89 |
| 4. Discussing whether PrEP is a good option for a patient. | 3.57 (1.21) |
0.89 |
| 5. Discussing the potential side effects of the antiretroviral medications used for PrEP (emtricitabine and tenofovir, together called Truvada) with a patient. |
3.21 (1.28) |
0.85 |
| 6. Determining whether a patient has a contraindication to using PrEP. | 3.31 (1.24) |
0.87 |
| 7. Prescribing PrEP to a patient for whom PrEP was appropriate and no contraindications were apparent. |
3.55 (1.26) |
0.86 |
| 8. Following patients on PrEP to monitor for side effects. | 3.46 (1.30) |
0.87 |
| 9. Following patients on PrEP to test them for HIV. | 3.85 (1.19) |
0.84 |
Notes: Item descriptive statistics are reported for primary care physicians from 10 U.S. cities (N=280). All descriptive statistics apply to items following reverse-coding.
PrEP, pre-exposure prophylaxis; R, items reverse-coded for scoring.